OncLive TV

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses considerations for selecting between FDA-approved companion diagnostic assays for measuring PD-L1 expression in triple-negative breast cancer.

Anita Lavery, MD, MRCP, discusses the decline in esophageal cancer diagnoses in Ireland during the COVID-19 pandemic.

Omar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.

Yelena Y. Janjigian, MD, discusses the FDA approval of nivolumab plus chemotherapy in frontline gastric cancer.

Robert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

Dickran G. Kazandjian, MD, discusses novel therapeutic targets in multiple myeloma.

Jason Zhu, MD, discusses the process of stratifying treatments for patients with node-positive prostate cancer.

Kelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

Abdulraheem Yacoub, MD, discusses efficacy and safety results with parsaclisib in myelofibrosis.

Andre H. Goy, MD, discusses the durability of response with brexucabtagene autoleucel in mantle cell lymphoma.

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

Suthee Rapisuwon, MD, discusses the potential utility of toripalimab in melanoma subtypes.

Christopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Edward Kim, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microspheres in hepatocellular carcinoma.

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.